FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Publishing timestamp: 2025-01-28 19:31:20
Summary
The FDA approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding its use to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease. This approval could transform how doctors treat patients with this condition, which is one of the leading causes of death in the U.S. The drug has shown significant health benefits beyond regulating blood sugar and suppressing appetite.
Sentiment: POSITIVE
Keywords: business news, biotechnology, health care industry, lilly drn, diabetes, novo nordisk a/s, breaking news: business, science, kidney disease, biotech and pharmaceuticals, pharmaceuticals, united states, fda, business,